TechNVision Ventures Limited has announced that its affiliate Emagia launched Gia AlphaCash™, a new AI Cash Discovery SuperAgent designed to help CFOs and finance leaders unlock trapped working capital by identifying receivable accounts most likely to generate the largest and fastest cash conversion. The announcement was made through a corporate filing dated March 20, 2026.

Revolutionary AI Cash Discovery Technology

Gia AlphaCash™ introduces what Emagia calls "Alpha Accounts"—focused customer accounts that can unlock maximum cash in the shortest time frame. The platform analyzes multiple financial and operational signals across enterprise systems to identify high-impact accounts and recommend optimal actions to accelerate collections and improve liquidity.

Key Performance Benefits

Organizations deploying Gia AlphaCash™ can achieve measurable improvements in working capital performance within 7 days of implementation. The platform delivers significant operational enhancements across multiple financial metrics.

Integrated AI Agent Ecosystem

At the core of the platform is the Alpha Account Discovery Agent, which works in coordination with Gia Collect™, Emagia's AI agent for collections. Gia Collect™ communicates with customers through voice, email, text, and digital channels while supporting electronic payments to accelerate collections outcomes. Together, these AI agents orchestrate an intelligent cash recovery strategy that includes receivables intelligence, Alpha account discovery, intelligent prioritization of collections activities, accelerated dispute resolution, and continuous AI learning based on payment outcomes.

Enterprise Integration Capabilities

Gia AlphaCash™ is designed for multinational enterprises, private equity portfolio companies, and global shared services organizations managing complex receivables environments. The AI SuperAgent offers flexible deployment options:

• Offline Operation: File upload functionality for standalone use
• Online Integration: Seamless integration with leading ERP platforms
• Supported Platforms: SAP, Oracle, NetSuite, and Workday

Management Commentary

Veena Gundavelli from Emagia emphasized the platform's strategic value: "Emagia is focused on empowering finance leaders with intelligence and tools needed to help their companies stay ahead of their competitors. Gia AlphaCash™ introduces AI Cash Discovery Agents that continuously analyze receivables data to pinpoint the accounts that can unlock the most cash in the shortest time. This allows CFO organizations to focus their efforts where it matters most and significantly accelerate working capital."

About the Companies

Emagia provides AI-powered Autonomous Finance platforms that help global enterprises transform Order-to-Cash operations. The Emagia platform deploys intelligent AI agents across credit, collections, cash application, deductions management, and payments to accelerate working capital and modernize finance operations. TechnVision Ventures Limited positions itself as a pioneer in creating next generation enterprise software business, innovating and incubating new ideas while fostering entrepreneurship in emerging technology areas.

TechNVision Ventures Ltd has announced a significant collaboration through a BSE filing dated March 18, 2026, regarding a Memorandum of Understanding between its affiliate Solix Technologies and Symbiosis Center for Entrepreneurship & Innovation. The MoU establishes a Center of Excellence in New Drug Development and Drug Repurposing, marking a strategic advancement in AI-driven healthcare innovation.

Strategic Partnership Details

The collaboration brings together Solix Technologies and Symbiosis Center for Entrepreneurship & Innovation in partnership with Symbiosis Medical College for Women to create a comprehensive research ecosystem. The MoU was formalized during TAL HealthFest 2026, demonstrating the commitment of both institutions to advance innovation at the intersection of Artificial Intelligence, biomedical research, and translational medicine.

Center of Excellence Framework

The Center of Excellence aims to integrate multiple research methodologies to accelerate drug discovery processes. The initiative combines computational intelligence with clinical validation to address current challenges in pharmaceutical development.

Core Integration Areas:

• Computational intelligence and AI-driven in-silico modeling
• Molecular validation frameworks
• In-vivo translational research

Initial Research Focus:

• Alzheimer's disease therapeutics
• Priority Antimicrobial Resistant (PAMR) pathogens

The collaboration leverages Solix's 25+ years of expertise in end-to-end data lifecycle management, governance, and Enterprise AI, combined with SMCW's clinical, translational, and biomedical research strengths.

Addressing Industry Challenges

The drug discovery and development landscape faces significant obstacles including high pre-clinical attrition rates, extended development timelines, and escalating R&D costs. This initiative aligns with national missions supported by India's DBT, ICMR, DST, and AMR action plans, contributing toward scientific self-reliance and healthcare innovation.

Leadership Vision and Impact

According to Mr. Sai Gundavelli, Founder & CEO of Solix Technologies, the partnership focuses on intelligent data harmonization and AI-driven translational science to accelerate therapeutic breakthroughs while reducing pre-clinical risk. Dr. Saptarishi Ghosh, CEO of SCEI at Symbiosis International University, emphasized that the collaboration strengthens their mission to empower women in medicine and advance translational healthcare research.

Technology and Research Integration

Mr. Murali Krishnam, VP - Pharma AI Product Strategy at Solix Technologies, highlighted the company's leadership in advanced Semantic Layering and Neuro-Symbolic AI. The platform addresses the complexity of integrating in-silico, in-vitro, and in-vivo research data ecosystems, enabling organizations to unlock unified insights and transform research into real-world impact.

The Center of Excellence will identify and validate novel therapeutic targets, develop CNS-active and antimicrobial lead molecules, and repurpose approved and investigational drugs. Additionally, it will enable industry collaboration and CRO services, support intellectual property generation, and train undergraduate, postgraduate, and PhD scholars in translational drug development.